Amy Selly, CNP, AOCNP

home / authors / amy-selly-cnp-aocnp

Amy Selly, CNP, AOCNP, is the medical oncology advanced practice provider lead at Allina Health.

Articles

Supporting Cancer Survivors: The Clinician's Role

Supporting Cancer Survivors: The Clinician's Role

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.

Working With Underserved Populations of Cancer Survivors

Working With Underserved Populations of Cancer Survivors

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the challenges facing cancer survivors from underserved populations.

The Role of Support in Cancer Survivorship

The Role of Support in Cancer Survivorship

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the role support plays in the cancer survivor experience.

Challenges Facing Cancer Survivors

Challenges Facing Cancer Survivors

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the varying challenges facing cancer patients and survivors.

Seeing Cancer as a Chronic Illness

Seeing Cancer as a Chronic Illness

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses how cancer as a chronic illness impacts definitions of survivorship.

Holistically Defining Cancer Survivorship

Holistically Defining Cancer Survivorship

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the different definitions of cancer survivorship.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Published: August 29th 2022 | Updated: December 22nd 2024
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: December 22nd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Published: July 15th 2022 | Updated: December 22nd 2024
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
Emerging data on oral selective estrogen receptor degraders
Published: November 25th 2024 | Updated: December 22nd 2024
Emerging data on oral selective estrogen receptor degraders